Atul Kothari, MD
Infectious Disease · North Little Rock, ARNPI 1265749626
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $624 of the $763 with a category attached, or 81.8%. It is spread thinly across 18 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations.
Across 32 payments — averaging $23.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$161
- AbbVie$85
- Merck$60
- Mallinckrodt Hospital Products Inc.$59
- United Therapeutics Corporation$53
- Melinta Therapeutics, LLC$50
- plus $295 from 12 others
What the payments were for
- Food & beverage$62482%
- Education$13918%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 3 | $161 |
| AbbVie | 5 | $85 |
| Merck | 3 | $60 |
| Mallinckrodt Hospital Products Inc. | 2 | $59 |
| United Therapeutics Corporation | 2 | $53 |
| Melinta Therapeutics, LLC | 2 | $50 |
| ANI Pharmaceuticals, Inc. | 2 | $47 |
| Gilead | 2 | $40 |
| Electromed, Inc. | 2 | $30 |
| La Jolla Pharmaceutical Company | 1 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Theratechnologies Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Viiv Healthcare Company | 1 | $15 |
| Nevro Corp. | 1 | $13 |
How this compares
$763 in reported general payments places this provider in the 60th percentile of 36 infectious disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vancomycin Hcl | 77 | $16,897 |
| CeftriaxoneCeftriaxone Sodium | 104 | $11,769 |
| ErtapenemErtapenem Sodium | 11 | $7,786 |
| Rifampin | 18 | $2,487 |
| Ethambutol Hcl | 22 | $1,145 |
| Azithromycin | 27 | $891 |
| Doxycycline Hyclate | 27 | $539 |
| Cefazolin Sodium | 18 | $317 |
| Cephalexin | 12 | $276 |
| Ciprofloxacin Hcl | 11 | $259 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $60 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in North Little Rock
- Amanda NovackNorth Little Rock$1K
- Mallory SmithNorth Little Rock$282
- Daniel YoungBentonville$65K
- James NewtonFayetteville$15K
- Stephen HenniganFayetteville$9K
- Andrew EbersRogers$2K
- Jeremy BariolaLittle Rock$2K
- Kevin DavisFort Smith$2K
- Naveen PatilLittle Rock$1K
- Katherine FerrenLittle Rock$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.